Bispecific antibodies (bsAbs) are engineered to target 2 different epitopes simultaneously. About 75% of the 16 clinically ...
Journal of Nuclear Medicine September 2024, jnumed.124.268151; DOI: https://doi.org/10.2967/jnumed.124.268151 ...
Journal of Nuclear Medicine September 2024, jnumed.124.267489; DOI: https://doi.org/10.2967/jnumed.124.267489 ...
Journal of Nuclear Medicine September 2024, jnumed.124.268797; DOI: https://doi.org/10.2967/jnumed.124.268797 ...
Journal of Nuclear Medicine September 2024, jnumed.124.268011; DOI: https://doi.org/10.2967/jnumed.124.268011 ...
Journal of Nuclear Medicine September 2024, jnumed.124.268145; DOI: https://doi.org/10.2967/jnumed.124.268145 ...
Journal of Nuclear Medicine September 2024, jnumed.124.267624; DOI: https://doi.org/10.2967/jnumed.124.267624 ...
Journal of Nuclear Medicine September 2024, jnumed.124.267736; DOI: https://doi.org/10.2967/jnumed.124.267736 ...
Journal of Nuclear Medicine September 2024, jnumed.123.267215; DOI: https://doi.org/10.2967/jnumed.123.267215 ...
Journal of Nuclear Medicine September 2024, jnumed.124.267964; DOI: https://doi.org/10.2967/jnumed.124.267964 ...
Journal of Nuclear Medicine September 2024, jnumed.124.267578; DOI: https://doi.org/10.2967/jnumed.124.267578 ...
Objectives Primary and metastatic bone cancer are significant sources of morbidity and mortality in cancer patients. Available treatments include bisphosphonates, anti-inflammatory and opioid pain ...